Figure 1.
OS and PFS of patients with relapsed THRLBCL treated with CD19-CART therapy in the CIBMTR registry.

OS and PFS of patients with relapsed THRLBCL treated with CD19-CART therapy in the CIBMTR registry.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal